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Abstract 
HOX genes encode a family of transcriptional regulators that are involved in pattern formation and 
organogenesis during embryo development. In addition, these genes play important roles in adult 
tissues and some of the dysregulated HOX genes are associated with cancer development and 
metastasis. Like many other HOX genes, HOXC9 is aberrantly expressed in certain breast cancer 
cell lines and tissues; however, its specific functions in breast cancer progression were not 
investigated. In the present study, we demonstrated that HOXC9 overexpression in breast cancer 
cell lines such as MDA-MB-231 and MCF7 increased the invasiveness but reduced the proliferation 
of cells, resembling a phenotype switch from a proliferative to an invasive state. Furthermore, the 
reciprocal result was detected in MCF7 and BT474 cells when the expression level of HOXC9 was 
reduced with siRNA. The clinical impact of HOXC9 in breast cancer was interpreted from the 
survival analysis data, in which high HOXC9 expression led to considerably poorer disease-free 
survival and distant metastasis-free survival, especially in lymph node-positive patients. Together, 
the prognostic relevance of HOXC9 and the HOXC9-derived phenotypic switch between 
proliferative and invasive states in the breast cancer cell lines suggest that HOXC9 could be a 
prognostic marker in breast cancer patients with lymph node metastasis and a target for 
therapeutic intervention in malignant breast cancer. 
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Introduction 
HOX genes are homeobox genes that function as 
transcription factors. In humans, a total of 39 HOX 
genes have been assigned to 13 paralogous groups in 
four separate clusters termed HOXA, HOXB, HOXC, 
and HOXD. Much is known about HOX gene 
structure and molecular functions of HOX protein in 
determining body patterning during embryogenesis; 
in addition to this, many studies have also revealed 
important roles of HOX genes in adult tissues and 
cancer [1-3]. In particular, several Hox genes, such as 
Hoxb6, Hoxc6, Hoxb7, Hoxa9, Hoxb9, Hoxd4, and Hoxd9, 
were identified as being differentially expressed in a 
spatial and temporal manner in the mammary glands 
of subadult and pregnant animals [4, 5].  
The murine Hox paralog group 9 genes, Hoxa9, 
Hoxb9, and Hoxd9 have been reported to function 
together to control the expansion and/or 
differentiation of the mammary epithelium ductal 
system in pregnancy [6]. Previous study has shown 
that HOXA9 is significantly downregulated in breast 
cancer and is correlated with disease aggressiveness 
[7]. In contrast, HOXB9 is overexpressed in breast 
cancer and promotes disease progression [8]. 
Aberrant expression of HOXD9 in breast cancer has 
also been reported [9, 10]; however, its functional 
consequences had not been investigated yet. HOXC9, 
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another member of the HOX paralog 9 group, is also 
expressed in adult mammary glands; however, its 
specific roles in the development of mammary tissue 
after pregnancy as well as in breast cancer have not 
yet been determined.  
A previous report analyzing DNA methylation 
patterns demonstrated that the CpG island at the 
promoter region of HOXC9 was methylated in 
primary breast cancer samples, implying that HOXC9 
might be silenced in this condition [11]. However, we 
previously found that HOXC9 gene expression was 
upregulated in breast cancer [12]. This discrepancy 
may imply that the expression of HOXC9 and its 
functional role could vary depending on cancer type 
or aggressiveness. Therefore, in this study, the roles of 
HOXC9 in breast cancer biology were determined by 
studying its effect on cell proliferation and invasion. 
Materials and Methods 
Cell culture, plasmids, siRNA, and transfection 
MCF7, BT474, and MDA-MB-231 cells were 
cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; WelGENE Inc., Daegu, Korea) 
supplemented with 10% fetal bovine serum (FBS; 
WelGENE Inc.) and 1× antibiotic-antimycotic solution 
(WelGENE Inc.). For overexpression studies, a 
pCMV6 expression vector containing full-length 
cDNA of the HOXC9 gene and Myc-DDK-tag 
(#RC208833; Origene, Rockville, MD, USA) was 
transfected in MDA-MB-231 cells using Attractene 
reagent (Qiagen). As a control, pCMV6 empty vector 
was transfected. The cells were treated with G418 
(Gibco; 300 μg/ml) for 2–3 weeks to generate stable 
cell lines. The same set of plasmid vector was used for 
transient transfection of MCF7 cells. For the 
knockdown experiments, MCF7 and BT474 cells were 
transfected with ON-TARGET plus SMARTpool 
siRNA targeting HOXC9 (#L-012341-00-0005; Thermo 
Scientific) or control siRNA by using G-Fectin 
transfection reagent (Genolution, Seoul, Korea).  
Total RNA isolation and RT-PCR  
Total RNA was isolated from cultured cells 
using TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA). Reverse transcription was conducted with 1 μg 
of total RNA using ImProm-llTM Reverse 
Transcriptase (Promega, Madison, WI, USA). PCR 
was performed using Taq polymerase (Bioneer, 
Seongnam, Korea). Primer sequences of HOXC9 were 
as follows: forward, 5’- GGG AGG GTT CAG TGT 
TGA GA-3’ and reverse 5’- GGG ATG ACC TGG ACC 
AAA TA-3’. For semiquantitative analysis, the Multi 
Gauge V3.0 software (Fuji, Tokyo, Japan) was used. 
β-actin mRNA was used as the invariant control. All 
experiments were performed in triplicate, and 
representative examples of the data are shown. 
Western blotting 
Cells were lysed in Nondet P-40 (NP-40) lysis 
buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% 
NP-40, and protease-inhibitor cocktail). Protein 
concentrations were estimated by the BCA Protein 
Assay Kit (Thermo). The primary antibodies used 
were anti-DDK-tag mouse mAb (Origene) and 
anti-β-actin (Sigma, St. Louis, MO, USA). After 
immune blotting, the signals were detected using 
SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL USA).  
MTT assay 
Cell proliferation was measured using the MTT 
assay. Cells were plated in 96-well plates at a density 
of 5 × 103 cells per well. On the next day, the cells were 
stained with 20 μl of 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 3.5 
hours at 37°C, followed by removal of the culture 
medium and incubation with 100 μl of MTT solvent (4 
mM HCl and 0.1% NP40, both in isopropanol). After 
15-minute incubation, the absorbance was measured 
with an ELISA reader (SOFTmax PRO) at 560 nm. All 
experiments were performed in triplicates. 
Matrigel invasion assay 
A Matrigel invasion assay was performed using 
Matrigel™ (BD) as previously described [13]. After 
24–72 hours, the invading cells were stained with the 
fluorochrome 4’,6-diamidino-2-phenylindole (DAPI) 
and observed by fluorescent microscopy. The 
acquired images were analyzed using the ImageJ 
software.  
In silico analysis  
To analyze HOXC9 expression patterns in breast 
cancer tissues, we used the web-accessible database 
GENT (Gene Expression across Normal and Tumor 
tissue), which provides gene expression patterns for 
diverse human cancer and normal tissues from more 
than 34,000 samples, profiled by Affymetrix U133A or 
U133plus2 platforms [14]. In this database, datasets 
have been pre-processed by the MAS5 algorithm and 
normalized to a target density of 500. For the survival 
analysis, the MTCI Breast Cancer Survival Analysis 
Tool (http://glados.ucd.ie/BreastMark/) was used. 
The MTCI developed the algorithm BreastMark, 
which integrates gene expression and survival data 
from 26 datasets on 12 different microarray platforms 
corresponding to ~17,000 genes in up to 4,738 
samples. 
Statistical analysis 
Data are expressed as mean values with 
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standard error of the mean. Statistical differences 
were determined by a Student’s t-test. A p value of 
<0.05 was considered statistically significant. 
Results 
Switch from a proliferative to an invasive 
phenotype by HOXC9 expression  
HOXC9 is a candidate gene for dysregulation in 
breast cancer. In our previous study, most of the 
breast cancer cell lines studied, except for the 
MDA-MD-231 cell line, showed higher HOXC9 
expression than MCF10A normal breast epithelial 
cells did [12]. Therefore, for further experiments, we 
selected the MDA-MB-231 cell line as a model system 
for gain-of-function studies. The forced expression of 
HOXC9 in MDA-MB-231 cells upon transfection with 
the expression plasmid harboring the HOXC9 was 
initially analyzed by Western blotting after sustained 
drug selection (Fig. 1A). After that, to assess the effect 
of HOXC9 overexpression on tumor cell proliferation 
and invasion, MDA-MB-231 cells stably expressing 
HOXC9 were generated (see Materials and Methods), 
and then three stable cell lines (231:C9 #1, 231:C9 #2, 
and 231:C9 #3) expressing high levels of HOXC9 were 
selected (Fig. 1B).  
 
Figure 1. Effect of HOXC9 overexpression on cancer cell proliferation and invasion. (A) Western blotting to detect HOXC9 protein expression in MDA-MB-231 cells 
transfected with empty vector (231:emp) and HOXC9 expression vector (231:C9). Anti-DDK antibody was used. Arrow indicates the expected size of HOXC9-DDK protein. 
(B) RT-PCR result showing overexpression of HOXC9 in three independent MDA-MB-231 clones (231:C9 #1, 231:C9 #2, and 231:C9 #3). Two clones harboring the empty 
vector (231:emp #1 and 231:emp #2) were used as controls. (C) The MTT assay was performed to measure cell viability. The proliferation activity was compared between three 
clonal cells expressing HOXC9 (231:C9 #1, 231:C9 #2, and 231:C9 #3), and three types of control cells (231:emp #1, 231:emp #2, and parent MDA-MB-231 [231] cells). (D) The 
Matrigel invasion assay was performed to measure invasion ability. Representative images showing the different number of invading cells between 231:emp and 231:C9 cells are 
presented on the right side. (E) RT-PCR analysis of HOXC9 expression in MCF cells transfected with the empty vector (MCF7:emp) or HOXC9 expression vector (MCF:C9): 
proliferation (F) and invasion analyses (G) were performed. *; p < 0.05, **; p < 0.01, ***; p < 0.001 vs. parental MDA-MB-231 or MCF7:emp control cells.  
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Figure 2. Effect of HOXC9 knockdown on MCF7 and BT474 cells. (A) RT-PCR 
result showing the suppression of HOXC9 expression in si_HOXC9 treated cells. 
Nonspecific siRNA (si_Con) was used as the control. The MTT assay (B) and Matrigel 
invasion assay (C) were performed to measure cell proliferation and invasion ability, 
respectively. *; p < 0.05, **; p < 0.01 vs. si_Con treated cells. 
 
The MDA-MB-231 cells overexpressing HOXC9 
showed statistically significant reduction of cell 
proliferation as compared to the cells transfected with 
the empty vector and parental MDA-MB-231 cells 
(Fig. 1C), whereas HOXC9 overexpression enhanced 
the invasive capacity compared to control cells (Fig. 
1D). When MCF7 cells were tested after HOXC9 
overexpression (Fig. 1E), similar results were 
generated: overexpression of HOXC9 reduced 
proliferation and increased invasiveness of the cells 
(Fig. 1F and G).  
 To determine whether these phenotypes could 
be reversed when HOXC9 was knocked down, we 
examined the effect of siRNA targeting HOXC9 on cell 
proliferation and invasion by using the MCF7 and 
BT-474 cell lines. The inhibition of HOXC9 expression 
significantly increased cell proliferation but decreased 
invasiveness (Fig. 2A-C).  
Correlation between HOXC9 expression and 
prognosis in breast cancer patients with lymph 
node metastasis 
We have previously shown that HOXC9 is a 
candidate gene that is upregulated in malignant 
tissues as compared to non-malignant tissues [12]. 
This is consistent with the information obtained from 
GENT (http://medical-genome.kribb.re.kr/GENT/) 
[14], where HOXC9 expression was higher in breast 
cancer samples as compared to normal samples (Fig. 
3A; data from 2, 662 breast-cancer vs. 267 
breast-normal, profiled by the Affymetrix U133plus2 
platform). To assess the effect of HOXC9 expression 
on the prognosis of breast cancer patients, disease-free 
survival (DFS) and distant metastasis-free survival 
(DMFS) curves were drawn using BreastMark of the 
MTCI Breast Cancer Survival Analysis Tool 
(http://glados.ucd.ie/BreastMark/). BreastMark is 
an algorithm that integrates gene expression and 
survival data from 26 datasets on 12 different 
microarray platforms. The number of samples used 
for analysis depends on how many platforms have 
probes for an interesting gene and relevant clinical 
data. A total of 1533 samples, including 767 events, 
were examined during analysis of DFS for all patients. 
This analysis revealed that there was no significant 
difference between the HOXC9-positive and 
HOXC9-negative groups (p = 0.058) (Fig. 3B). 
However, high HOXC9 expression had a significant 
impact on DMFS for all patients (n = 577, number of 
events = 187, p = 0.000208) (Fig. 3C). Subgroup 
analysis showed that high HOXC9 expression was 
correlated with poor prognosis for DFS (number of 
events = 278) and DMFS (number of events = 109) in 
lymph node–positive patients (n = 633 for DFS, n = 
257 for DMFS) (Fig. 3D and E), but not in lymph 
node–negative patients (Fig. 3F and G). 
Discussion 
 HOXC9 is one of the HOX genes that are 
dysregulated in breast cancer cells. In order to 
understand the functional role of HOXC9 in breast 
cancer, we performed overexpression and 
knockdown experiments in breast cancer cell lines 
and examined the effect of HOXC9 on cancer cell 
proliferation and invasion. Forced expression of 
HOXC9 resulted in increased invasiveness, whereas it 
showed negative effects on cell proliferation. HOXC9 
knockdown exhibited opposite effects, promoting 
cancer cell proliferation. This HOXC9-driven 
switching phenotype was induced in different breast 
cancer cell lines, regardless of cell type: the cell lines, 
MCF7 and MDA-MB-231, that were originally derived 
from the metastatic site of breast cancer and classified 
as the same tumor type, that is, metastatic 
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adenocarcinoma, and BT474, originally isolated from 
the primary tumor, classified as an invasive ductal 
carcinoma [15]. 
Previously, high HOXC9 expression has been 
reported to be associated with neuroblastoma 
differentiation and as a prognostic marker for better 
survival in neuroblastoma patients by inducing 
growth arrest [16]. On the basis of these results, it is 
interesting to note that the endogenous expression 
level of HOXC9 in the different breast cancer cell 
lines, that is, MCF7, BT474, and MDA-MB-231 [12], 
might explain the properties of each cell line. High 
expression of HOXC9 in MCF7 and BT474 might 
account for the noninvasive, differentiated 
luminal–like features, whereas low expression in 
MDA-MB-231 could be related to the poorly 
differentiated basal-like features and highly 
aggressive properties. Although our knowledge on 
the regulation of HOXC9 expression in malignant 
human mammary epithelial cells is still limited, the 
differences in the expression level of HOXC9 in the 
MCF7 and MDA-MB-231 cell lines could be partially 
explained by the different methylation patterns, since 
the CpG island around the HOXC9 promoter region 
was reported to be unmethylated in MCF7 but highly 
methylated in MDA-MB-231 [11].  
 
Figure 3. Prognostic significance of HOXC9 expression in breast cancer patients. (A) Publically available data retrieved from GENT (http://medical-genome.kribb.re.kr/GENT) 
show that HOXC9 is upregulated in breast cancer tissues. breast-C: breast cancer tissues, breast-N: normal breast tissues. Each circle represents an individual tissue sample. Data 
are shown as boxplots. The Y axis of the plot indicates normalized expression measures. The box extends from the 25th to 75th percentiles and the line in the middle of the box 
is plotted at the median. Significance was analyzed using an unpaired t-test (p = 2.913E-11). (B-G) Survival analysis using the MTCI breast cancer survival analysis tool 
(http://glados.ucd.ie/BreastMark/). Disease free survival (DFS) (n = 1533, number of events = 767, hazard ratio = 1.164 [0.9947 - 1.363], p = 0.058) (B) and distant metastasis–free 
survival (DMFS) (n = 577, number of events = 187, hazard ratio = 1.758 [1.3–2.379], p = 0.000208) (C) in all patients. DFS (n = 633, number of events = 278, hazard ratio = 1.382 
[1.074–1.778] p = 0.0116) (D) and DMFS (n = 257, number of events = 109, hazard ratio = 2.17 [1.483–3.176], p = 4.351e-05) (E) in lymph node–positive patients. DFS (n = 538, 
number of events = 163, hazard ratio = 1.03 [0.7574–1.401], p = 0.85) (F) and DMFS (n = 276, number of events = 57, hazard ratio = 1.289 [0.7646 – 2.174], p = 0.339) (G) in 
lymph node–negative patients. 
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The current finding about the effect of forced 
expression of HOXC9 in MDA-MB-231 was somewhat 
unexpected. When HOXC9 was overexpressed, the 
proliferative activity decreased, as reported in the case 
of neuroblastoma [16]. HOXC9 has also been reported 
to induce endothelial cell quiescence, inhibiting 
proliferation and thus keeping the vasculature in the 
resting state [17]. When HOXC9 is suppressed by 
hypoxia, an important physiological stimulus for 
angiogenesis in the tumor site, the endothelial cells 
become activated and start to proliferate, thereby 
promoting the angiogenic activity [17, 18]. However, 
interestingly, the invasiveness increased here along 
with the decrease in proliferation, resembling a 
phenotype switch from a proliferative to an invasive 
state (Fig. 1). Furthermore, the reciprocal result was 
detected in MCF7 and BT474 cells when the 
expression level of HOXC9 was decreased with 
siRNA (Fig. 2). Recently, this kind of phenotype 
switching has been reported in melanoma cells, and 
was considered as a kind of alternative resistance 
mechanism to the therapeutics [19-21]. Interestingly, a 
similar reciprocal switching phenotype has also been 
reported in breast cancer cells [22-24].  
Breast cancer–related death is mainly due to 
metastasis to other organs and the concomitant loss of 
function of that organ rather than the lesions in the 
breast itself. Local invasion and migration are the 
initial steps of the multi-step process of metastasis 
[25]. The accumulating evidence indicates that 
epithelial-mesenchymal transition (EMT) plays a 
critical role in metastasis; the genes involved in EMT 
promote invasion and migration but suppress 
proliferation [25, 26]. In the current study, we did not 
confirm the relatedness to EMT; however, HOXC9 
was found to promote the invasion and suppress the 
proliferation of breast cancer cells. This result is in 
good agreement with the survival analysis data of 
breast cancer patients for whom high level expression 
of HOXC9 correlated well with poor prognosis in 
DMFS, especially in the case of lymph node–positive 
patients (Fig. 3). Together, these data suggest that 
HOXC9 could be a prognostic marker in breast cancer 
patients with lymph node metastasis and a target for 
therapeutic interventions in malignant breast cancer.  
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